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Abstract
This review summarizes the chromosomal changes detected by molecular cytogenetic approaches in esophageal
squamous cell carcinoma (ESCC), the ninth most common malignancy in the world. Whole genome analyses of
ESCC cell lines and tumors indicated that the most frequent genomic gains occurred at 1, 2q, 3q, 5p, 6p, 7, 8q, 9q,
11q,12p,14q,15q,16,17,18p,19q,20q,22qandX,withfocalamplificationsat1q32,2p16-22,3q25-28,5p13-15.3,
7p12-22, 7q21-22, 8q23-24.2, 9q34, 10q21, 11p11.2, 11q13, 13q32, 14q13-14, 14q21, 14q31-32, 15q22-26,
17p11.2, 18p11.2-11.3 and 20p11.2. Recurrent losses involved 3p, 4, 5q, 6q, 7q, 8p, 9, 10p, 12p, 13, 14p, 15p, 18,
19p, 20, 22, Xp and Y. Gains at 5p and 7q, and deletions at 4p, 9p, and 11q were significant prognostic factors for pa-
tients with ESCC. Gains at 6p and 20p, and losses at 10p and 10q were the most significant imbalances, both in pri-
mary carcinoma and in metastases, which suggested that these regions may harbor oncogenes and tumor
suppressor genes. Gains at 12p and losses at 3p may be associated with poor relapse-free survival. The clinical ap-
plicability of these changes as markers for the diagnosis and prognosis of ESCC, or as molecular targets for person-
alized therapy should be evaluated.
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Esophageal Carcinoma
Cancer of the esophagus is the ninth most common
malignancy in the world, but its incidence varies consider-
ably among geographical regions (Lam, 2000), with a high
incidence in China, Japan, Singapore and Puerto Rico
(INCA, 2009a). The American Cancer Society estimated
that around 16,470 new cases of esophageal carcinoma oc-
curred in the USA in 2008 (American Cancer Society,
2009). In Brazil, esophageal cancer ranked sixth in cancer
mortality in 2000, with 5,307 deaths; about 10,550 new
cases were reported in 2008, with an incidence of 1.04-
19.07 per 1000,000 males and 0.39-7.58 per 100,000 fe-
males (INCA, 2009b).
The development of human esophageal cancer is pro-
gressive, involving the accumulation of genetic changes
that culminate in malignant transformation (Knudson,
1985; Somers and Schechter, 1992; Xue et al., 2006). An
early indicator of this process is the increased proliferation
of esophageal epithelial cells that morphologically pro-
gresses to basal cell hyperplasia, dysplasia, carcinoma in
situ and invasive carcinoma (Muñoz, 1997; Mandard et al.,
2000; D’Amico, 2006).
WiththeexceptionoftheUSA,esophagealsquamous
cell carcinoma (ESCC) is histologically the most prevalent
type of esophageal cancer worldwide and has a multi-
factorial origin. In addition to environmental components
(Crawford, 2004), several genetic factors are associated
with esophageal carcinogenesis, such as chromosomal
aneuploidy, allelic deletions, activation of oncogenes and
inactivation of tumor suppressor genes (Kuwano et al.,
2005). At the cellular level, these factors lead to disorders
of cell proliferation, differentiation and apoptosis (Koch et
al., 1994; McCabe and Dlamini, 2005; D’Amico, 2006;
Daigo and Nakamura, 2008; Khushalani, 2008).
Specific chromosomal aberrations have been identi-
fied as markers for the diagnosis and prognosis of solid tu-
mors (Tada et al., 2000; Yen et al., 2001; Shiomi et al.,
2003; Qin et al., 2004, 2005a,b, 2008; Wang et al., 2006).
Despite reports of numerous chromosomal alterations, no
particular diagnostic or prognostic chromosomal markers
have been described for esophageal carcinoma. The aim of
this review is to summarize the recurrent chromosomal
changes,suchasgainsandlossesinregionsthatmayharbor
Genetics and Molecular Biology, 33, 2, 205-213 (2010)
Copyright © 2010, Sociedade Brasileira de Genética. Printed in Brazil
www.sbg.org.br
Send correspondence to Ana Elizabete Silva. Laboratório de Cito-
genética e Biologia Molecular, Departamento de Biologia, Univer-
sidade Estadual Paulista ‘Júlio de Mesquita Filho’, Rua Cristóvão
Colombo 2265, 15054-000 São José do Rio Preto, SP, Brazil.
E-mail: anabete@ibilce.unesp.br.
Review Articleoncogenes and tumor suppressor genes that have been de-
tected in ESCC by molecular cytogenetic approaches.
These chromosomal imbalances may represent clinically
relevant markers for the diagnosis and prognosis of ESCC
or for the identification of novel therapeutic targets.
Molecular Cytogenetic Technologies Identify
Genomic Changes In Cancer
The primary cytogenetic technique used to investi-
gate the molecular pathogenesis of esophageal carcino-
genesis is DNA fluorescence in situ hybridization (FISH).
ThistechniqueusessmallfragmentsofDNAasfluorescent
probes that bind to specific chromosomal sequences of the
target DNA to which they show a high degree of comple-
mentarity (Bauman et al., 1980; Langer et al., 1981). FISH
probes are often derived from DNA fragments that vary
from a few hundred to 200,000 base-pairs; these fragments
are isolated, purified, amplified and labeled with fluoro-
chrome-conjugated nucleotides. The DNA probes hybrid-
ize to distinct DNA targets such as metaphase chromo-
somes, interphase nuclei, and extended chromatin fibers
and DNA fragments in a variety of biological specimens or
platforms, including isolated cells, tissue sections and bac-
terial artificial chromosomes (BAC) and oligonucleotide
arrays (Solinas-Toldo et al., 1997; Pinkel et al., 1998;
Speicher and Carter, 2005).
There are numerous variants of the FISH assay, with
the most effective for detecting extensive genomic imbal-
ances being comparative genomic hybridization (CGH).
CGH was originally developed as the competitive hybrid-
ization of a mixture of test DNA and normal reference
DNA, labeled with different fluorochromes, to metaphase
spreads of a normal specimen, i.e., metaphase CGH
(mCGH) (Kallioniemi et al., 1992; du Manoir et al., 1993).
In these conditions, chromosomal regions of the test DNA
that have normal copy numbers will show a balanced ratio
of hybridization with the test and control DNA, whereas
chromosomal regions with an excess or loss of copy num-
bers in the test DNA will show predominantly the color of
the hybridization in the normal template. The test DNA
used in the CGH assay can be extracted from dividing or
non-dividing cells from virtually all types of tissues, in-
cluding formalin-fixed specimens; the latter possibility al-
lows an informative overview of archived specimens. The
level of resolution of specific imbalances in the mCGH as-
say depends essentially on the condensation of the chromo-
somestowhichtheDNAmixishybridizedandrangesfrom
5 to 10 Mb (Kallioniemi et al., 1992; Speicher and Carter,
2005). Although it is possible to identify large regions in-
volved in low level of genomic gain or loss and small re-
gions with focal amplification, the resolution of the mCGH
is generally limited or insufficient for the identification of
specific chromosomal bands (Kallioniemi et al., 1992;
SpeicherandCarter,2005).Consequently,mCGHisgener-
ally used as a preliminary tool to infer potential genes lo-
cated in imbalanced regions and to confirm or support the
results of studies with higher resolution techniques, such as
array CGH (aCGH) or FISH with single gene probes (Na-
kakuki et al., 2002; Arai et al., 2003)
TheaCGHtechniquedetectschangesinchromosome
copy number at a much higher resolution than mCGH
(Solinas-Toldo et al., 1997; Pinkel et al., 1998). Instead of
using metaphase spreads as the template for hybridization,
the aCGH uses a collection of DNA inserts contained in
bacterial artificial chromosomes (BAC arrays) or oligo-
nucleotides (oligo-arrays) printed on a glass slide. As with
the mCGH, a differentially labeled mixture of DNAs from
thetestsampleandanormalreferencecontrolsampleishy-
bridizedwiththeselectedplatformandtheratioofthefluo-
rescence intensity of the test to reference DNA is
calculated. Using aCGH, changes in copy number can be
detected based on a few hundred kilobases of DNA se-
quences for BAC arrays or 30 kb for oligoarrays (Snijders
et al., 2001; Fiegler et al., 2003; Medical Genetics Labora-
tories, 2008). More recently, imbalances involving single
nucleotides have been detected by single nucleotide poly-
morphism (SNP)-based arrays, a type of DNA microarray
used to detect polymorphisms within a population (Sherry
et al., 2001).
Other variants of FISH technology include multi-
plex-FISH (M-FISH) and spectral karyotyping (SKY).
These procedures allow identification of the origin of each
chromosomal region in a metaphase cell by visualizing all
24humanchromosomesinasinglehybridization(Speicher
andCarter,2005).Inbothtechniques,theprobesetisapool
of differentially labeled DNAs for each of the 24 human
chromosomes. In M-FISH, the images for each fluoro-
chrome are collected individually and merged, and a com-
binatorial labeling algorithm identifies each chromosome
thatisthenvisualizedinpre-definedpseudocolor(Speicher
et al., 1996). In the SKY assay, a single image is captured
per cell and an interferometer is used to discriminate the
fluorochrome spectrum in each pixel, to which a pseudo-
color is assigned (Schröck et al., 1996). Both techniques
have been successful in clarifying complex chromosomal
rearrangements in solid tumors (Schröck and Padilla-Nash,
2000), including ESCC (Yen et al., 2003).
Together, the numerous variants of FISH technology
have allowed the accurate identification of chromosomal
DNA sequences of interest and facilitated the screening of
the whole genome for gains and losses associated with
carcinogenesis.
Genomic Imbalances In Escc Cell Lines
The few molecular cytogenetic studies of ESCC cell
linesreportedtodateindicatethatthesecelllinesarehighly
abnormal cytogenetically. In a study in which eight ESCC
cell lines were screened using mCGH, SKY and FISH with
single probes, the pooled CGH results revealed frequent
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7p, 7q, 8q, 9q, 11q, 12p, 14q, 15q, 16p, 16q, 17q, 18p, 19q,
20q, 22q and Xq), with frequent losses on 3p, 4, 5q, 6q, 7q,
9p and 18q. SKY analyses detected 195 translocations, 13
deletions and two duplications in the eight cell lines, with
the most frequently amplified genes being PIK3CA (3q26)
and TP63 (3q28). PIK3CA encodes the catalytic subunit of
phosphatidylinositol 3-kinase (PIK3), which uses ATP to
phosphorylate phosphatidylinositol (National Center for
Biotechnology Information, 2009a) and TP63 encodes a
protein involved in the development and maintenance of
stratifiedepithelialtissues(NationalCenterforBiotechnol-
ogy Information, 2009b). These oncogenes were amplified
in six and five cell lines, respectively (Yen et al., 2003).
Multiplegainsandlossesinvolvingdifferentchromo-
somal regions were also revealed by mCGH in ten ESCC
cell lines of the KYSE series (TE 1-6, 8-11, 13, and 15).
The most frequent losses were observed on chromosomal
arms3p,4p,4q,8p,9p,18qandXp,whereasthemostcom-
mon gains were noted on 1q, 3q, 5p, 7p, 8q, 9q, 11q, 18p,
20q and Xq. While focal loss was only identified at 11q23-
25, focal amplifications were detect at 1q32, 2p16-22,
3q25-28, 5p13-15.3, 7p12-22, 7q21-22, 8q23-24.2, 9q34,
10q21, 11p11.2, 11q13, 13q32, 14q13-14, 14q21, 14q31-
32, 15q22-26, 17p11.2, 18p11.2-11.3 and 20p11.2 (Shino-
miya et al., 1999; Pimkhaokham et al. 2000; Su et al.,
2006).
Yang et al. (2008a) recently reported cytogenetic ab-
normalities in the cell line KYSE 410-4 using M-FISH,
with chromosomal gains on 2q, 3, 8, 17p and X. An iso-
chromosome3qwasdetectedinthislineandmayrepresent
anintermediatemechanisminvolvedin3plossand3qgain.
For the cell line KYSE 180, M-FISH analysis detected loss
of DNA copy number on chromosomes 4p, 5q, 6q, 9, 10p,
12p, 13, 14p, 15p, 18p, 18q, 20, 22 and Y, and chromo-
somal gains and translocations mainly on chromosomes 1,
2p,3,4p,5p,5q,6p,7,8,10q,11,12q,14q,16,17q,19and
Xp. Seven derivative chromosomes involving chromo-
somes 5, 8, 12, 14, 15, 16, and 17 showed complex
translocations, each involving three or four chromosomes;
a loss of chromosomes 9, 13, and Y was also detected (Wu
et al., 2006).
Based on previous CGH studies that showed frequent
amplifications in 18p in esophageal cell lines (Shimada et
al., 1992; Pimkhaokham et al., 2000), Nakakuki et al.
(2002) used FISH to screen 29 ESCC cell lines and identi-
fied amplifications of 14 known genes and 21 uncharac-
terized transcripts in chromosome 18 amplicons. These
authors also investigated the corresponding levels of gene
expression by Southern-, dot- and northern-blotting. Only
four known genes (YES1, TYMS, HEC and TGIF) showed
amplification and corresponding over-expression. YES1
encodes a protein with tyrosine kinase activity, TYMS is
critical for DNA replication and repair, HEC is involved in
spindle checkpoint signaling and TGIF is a highly con-
served transcription regulator with a potential role in the
transmission of nuclear signals during development and in
adults. These findings suggested that these genes are in-
volved in 18p11.3 amplification and may be associated
with esophageal tumorigenesis.
Figure 1A summarizes these studies. The alterations
detected affected most of the genome and involved regions
harboring many known oncogenes and tumor suppressor
genes, as well regions not yet associated with such genes.
Although the level of molecular resolution of most of these
studies is low and inconclusive, these findings are promis-
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Figure 1 - Summary of copy number alterations in esophageal squamous
cell carcinomas (ESCC) analyzed by comparative genomic hybridization.
Regions with copy number gains are represented by thin lines on the right
side of the chromosome idiograms and amplifications are represented by
thickbarsonthesameside;regionsoflossarerepresentedbythinlineson
the left side of the idiograms. (A) In ESCC cell lines, the most frequent
genomic gains were observed in chromosomes 1, 2q, 3q, 5p, 6p, 7, 8q, 9q,
11q, 12p, 14, 15, 16, 17, 18p, 19q, 20q, 22q and X. Focal amplifications
were found at 1q32, 2p16-22, 3q25-28, 5p13-15.3, 7p12-22, 7q21-22,
8q23-24.2, 9q34, 10q21, 11p11.2, 11q13, 13q32, 14q13-14, 14q21,
14q31-32, 15q22-26, 17p11.2, 18p11.2-11.3 and 20p11.2. Recurrent
losses occurred at 3p, 4, 5q, 6q, 7q, 8p, 9, 10p, 12p, 13, 14p, 15p, 18, 20,
22, Xp and Y. (B) In clinical specimens, chromosomal gains were com-
mon in 1q, 2q, 3q, 5p, 6, 7, 8q, 9, 10, 11q, 12, 13q, 14q, 16p, 17, 18q, 20
and Xq, specifically in the regions 1p34, 2p24, 2q24-34, 3q22-ter, 7p12-
22, 8q13-qter, 11p11.2, 11q13, 12p11.2, 13q21-34, 17q12, 20q12-13 and
Xq27-28. Recurrent losses occurred at 1p, 3q, 4p, 5q, 6, 8p, 11q, 12q, 13q,
14q, 16q, 17q, 18q, 19, 21q, 22q and Y.ing in that they provide a starting point for further investi-
gations on the molecular pathogenesis of ESCC and the
development of new therapeutic approaches for such can-
cer.
Genomic Imbalances In Escc Tumors
Despiteadvancesinourunderstandingoftheriskfac-
tors and cellular derangements associated with esophageal
cancer,theclinicaltreatmentofthisdiseaseremainslargely
unaltered and long-term survival from this cancer remains
poor, with a 5-year survival rate of ~20% (Hsia et al.,
2003).
A combination of FISH, mCGH and aCGH has
shownthatchromosomes1,3,7,9,11,18,19and20havea
high frequency of alterations. In addition, genomic profiles
of primary carcinomas have revealed imbalances affecting
most of the chromosomes, such as gains on 1q, 3q, 5p, 7p,
8q, 11q, 13q, 18p, 20q and Xq, and losses on 1p, 3p, 4p, 8p,
9p, 18q, 19, 22q and Y. Focal losses at 9p13, focal gains at
5p15, 8p12-11.2, 8q24, 11q13 and 14q32, and amplifica-
tionsat1p34,2p24,2q24-34,3q22-ter,7p12-22,8q13-qter,
11p11.2, 11q13, 12p11.2, 13q21-34, 17q12, 20q12-13 and
Xq27-28 are also commons findings (Pack et al., 1999;
Shinomiya et al., 1999; Mayama et al., 2000; Yen et al.,
2001; Kamitani et al., 2002; Yen et al., 2003; Kwong et al.,
2004; Qin et al., 2004, 2005a,b, 2008; Sugimoto et al.,
2007). High-level amplifications have been observed in 30
regions and repeatedly involve 7p11.2 and 11q13. The ma-
jor gene amplified in the first of these regions is EGFR,
which encodes the epidermal growth factor receptor
(EGFR); activation of this receptor by its ligand results in
dimerization and tyrosine auto-phosphorylation that leads
to cell proliferation (Carneiro et al., 2008; National Center
for Biotechnology Information, 2009c). The second of
these regions harbors CCND1, a regulator of CDK kinases
required for the G1/s cell cycle transition (Carneiro et al.,
2008; National Center for Biotechnology Information,
2009d). Interstitial deletions in 1p, 3p, 5q, 6q, 11q and 12q
have also been detected (Pack et al., 1999).
Together, these observations indicate that chromo-
somal aberrations are common in clinical ESCC specimens
and suggest that chromosomes 1q, 3q, 5p, 6q, 8q,18p and
20q, particularly regions 1p34, 2p24, 2q24-34, 3q22-ter,
7p12-22, 8q13-qter, 11p11.2, 11q13, 12p11.2, 13q21-34,
17q12, 20q12-13 and Xq27-28, may contain ESCC-related
oncogenes; on the other hand, chromosomes 1p, 3p, 4p, 8p,
9p13, 9q and 19p may contain ESCC-related tumor sup-
pressor genes involved in the development and progression
of esophageal cancer (Figure 1B).
Early Genomic Changes and Imbalances
Associated With Tumor Staging
ESCC arises through multi-step genetic and cyto-
geneticalterations.However,thetimesequenceoftheseal-
terationsremainstobedetermined.Inthisregard,studiesin
which chromosomal aberrations are correlated with the
stage and clinical outcome of prognostic significance are
necessary in order to facilitate the selection of patients for
specific treatments.
Aninterestingrecentstudyexploredtheusefulnessof
M-FISH for the early diagnosis and risk prediction of pre-
cursor lesions of ESCC in tumor and premalignant lesions
in 113 patients (Yao et al., 2008). Elevated rates of aneu-
ploidy were frequently observed in chromosomes 3, 8, 10,
12, 17 and 20 in ESCC and its precursor dysplastic lesions.
These findings support the conclusion that the application
of a multi-target FISH assay to investigate chromosomal
aneuploidy at esophageal dysplastic sites may be useful in
predicting the risk of ESCC.
Theprogressionofdysplasticlesionstotheadvanced,
metastatic stage is accompanied by numerous genomic
changes, as indicated by mCGH analyses of ESCC lymph
node metastasis. Copy number gains have frequently been
detected at 1q, 1p36.32, 3q, 5p, 8q23-qter, 11q13-14,
5p14-pter, 6p, 20q, 7p22.3, 7q, 2p, 12p, 19p13.3 and 20p,
and DNA amplifications have been detected at 11q13,
2q12, 6p12-6q12, 7q21, 20q11.2 and 20p12; losses have
been detected at 18q, 3p, 9p, 5q14-23, 4q, 13 and 11q22-
qter (Qin et al., 2005a; Wang et al., 2006; Carneiro et al.,
2008; Qin et al., 2008).
Gains involving 3q, 5p, 1q and 11q13-14 and losses
involving 4 and 13q are significantly correlated with the
pathological stage, whereas a gain of 8q and loss of 4p are
linked to nodal metastasis; similarly, a gain of 2p and loss
of 4 and 11q14-qter are associated with distant organ me-
tastasis (Qin et al., 2004). Gains involving 1q, 3q, 5p and
11q13-14 and losses involving 4 and 13q are critical for the
development of ESCC, whereas a gain of 2p and 8q and
loss of 4 and 11q14-qter are later events associated with tu-
mor progression and thought to confer metastatic potential
to the disease. Nodal and distant organ metastases appar-
ently involve different genes (Qin et al., 2005b). Gains in-
volving3qand11q13andlossesinvolving3p,4q,5q14-23,
9pand18qhavebeendetectedinearlyandadvancedstages
of ESCC.
Deletions of 4p and 13q12-q14 and a gain of 5p are
significantly correlated with the pathological state. Losses
of 8p22-pter and 9p are more frequent in patients with ad-
vanced disease. A gain of 8q24-qter is more frequent in pa-
tientswithgrade3tumors(Yenetal.,2001).UsingmCGH,
Shiomi et al. (2003) observed that gains involving 3q, 8q,
11q13 and 14q were early events, while the loss of 3p, 5q,
13q and 21q and gain of 1p and Xq were later events in the
development of individual tumors.
Gains of 6p and 20p and losses of 10p and 10q are the
most significant imbalances in primary carcinoma and me-
tastasis, which suggests that these regions may harbor
oncogenes and tumor suppressor genes (Qin et al., 2005a).
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relapse-free survival (Kwong et al., 2004).
The Search For Relevant Oncogenes In Escc
In41primaryESCCinvestigatedwithCGH(Fujitaet
al. 2003), the expression of numerous genes, including the
cell cycle-regulator kinase gene BTAK (20q13.2-3) and
E2F1(20q11.2),whichplaysacrucialroleincellcyclereg-
ulation, was enhanced in ~10% of tumors. Other genes,
such as NCOA3 (20q12), which encodes a nuclear receptor
co-activator that enhances the transcriptional activator
function of nuclear hormone receptors, and DcR3
(20q13.3), which regulates apoptosis were up-regulated to
a lesser extent. Xu et al. (2007) detected NCOA3 over-
expression and an increased copy number in 46% and 13%
of 221 ESCCs, respectively. NCOA3 overexpression was
observed more frequently in late compared to early stages,
but there was no significant association between the ex-
pression of NCOA3 and lymph node metastases. These ob-
servations suggest that overexpression of NCOA3 as a
result of genomic gain or other molecular mechanisms
might provide a selective advantage for the development
and local invasion of certain subsets of ESCC.
To date, there has been no detailed analysis of loss of
heterozygosity (LOH) for chromosome 18q in ESCC.
However, LOH on chromosome 18q is common in several
cancers, with frequencies of 55%-67% in colorectal cancer
(Jen et al., 1994; Thiagalingam et al., 1996), 90% in pan-
creatic cancer (Hahn et al., 1996), 59% in ovarian cancer
(Lassus et al., 2001) and 40%-84% in head and neck squa-
mous cell carcinoma (Papadimitrakopoulou et al., 1998;
Pearlstein et al., 1998; Takebayashi et al., 2000). In these
cancers, frequent LOH on chromosome 18q correlates with
tumor growth, aggressive tumor behavior and tumori-
genesis. These findings suggest that chromosome 18q may
harbortumorsuppressorgenesforvariouscancers(Andoet
al., 2007). In a FISH analysis of the allelic imbalance of
chromosome 18q in ESCC resected samples from two out
of five patients showed a loss of one copy of chromosome
18q, and 13 of 46 ESCC samples (28.3%) showed loss of
almost all of chromosome 18q (Ando et al., 2007). The au-
thors suggested that the loss of 18q may play an important
role in the progression of ESCC.
Few studies have focused on the identification of al-
tered pathways and clinically applicable markers. Onco-
gene amplification was examined by DNA microarrays in
20 surgically resected ESCC and 57 oncogenes were found
to be amplified. Alterations in DNA copy number detected
by microarrays were compared to those obtained by
mCGH. DNA microarrays showed that eight oncogenes
(CCND1, FGF3/ FGF4, EMS1, SAS, ERBB2, PDGFRA,
MYC and BCL2) were amplified in 9 of 20 tumors. Al-
though ERBB2 expression was 23-fold greater than the
basal level in one case, the average level of gene amplifica-
tion was generally only 2-4-fold above the control value.
EMS1, CCND1 and FGF3/FGF4, which are all located on
11q13, were amplified in 7, 5 and 4 of 20 ESCC, respec-
tively, and were co-amplified in three tumors. EMS1 regu-
latestheinteractionsbetweencomponentsofadherens-type
junctions and organizes the cytoskeleton and cell adhesion
structuresofepitheliaandcarcinomacells(NationalCenter
for Biotechnology Information, 2009e). FGF3/FGF4
broadly regulate mitogenesis, cell survival and oncogenic
activity.
A comparison of genomic DNA microarray and
mCGH data showed that although most of the amplified
oncogenes were included in chromosomal regions for
which gains in DNA copy number were detected by
mCGH, not all of the amplified genes detected by micro-
arrays showed concomitant gains in the DNA copy number
in mCGH; this lack of correlation between the two tech-
niques confirmed the limited resolution of the mCGH as-
say. Microarrays of oncogenes are useful for the compre-
hensive identification of amplified oncogenes and for
analyzing specific chromosomal regions in which mCGH
analysisindicatesanincreaseinDNAcopynumber(Araiet
al., 2003).
FISH assays revealed the amplification of PLK1
(polo-like kinase 1), an essential gene for the maintenance
of genomic stability during mitosis (Feng et al., 2009); this
gene may therefore be a useful prognostic marker. An anal-
ysis of 108 ESCCs and nine ESCC cell lines revealed a fre-
quent gain of the genes MDS1 (myelodysplasia syndrome
1)andPRKCI(proteinkinaseC,iota),whichhavebeenim-
plicated in neoplastic transformation, and a positive corre-
lation between the level of PRKCI expression and tumor
size,lymphnodemetastasisandclinicalstage.PRKCIgene
amplification was highly correlated with protein over-
expression (Yang et al., 2008b).
EGFR expression is enhanced in many cancers and is
sometimesaccompaniedbygeneamplification.FISHanal-
ysis has shown that the EGFR gene is amplified in ESCC
(Sunpaweravongetal.,2005;Hanawaetal.,2006).Indeed,
EGFR gene overrepresentation (balanced gene and chro-
mosome 7 polysomy) and HER-2 amplification are com-
moneventsinESCC(Mimuraetal.,2005;Sunpaweravong
et al., 2005; Bizari et al., 2006).
Cyclin D1 (CCDN1) is a cell-cycle regulator and
oncogeneimplicatedinthepathogenesisofnumeroustypes
of tumors. Amplification of the CCDN1 gene is common in
ESCC and has been detected by FISH (Sheyn et al., 1997;
Jin et al., 2004; Manoel-Caetano et al., 2004; Sunpawe-
ravong et al., 2005; Bizari et al., 2006).
The correlation between the overexpression and am-
plification of oncogenes and patient survival has not been
extensively investigated. However, the survival of patients
withincreasedexpressionofBTAKorE2F1issignificantly
lower than that of patients without this alteration, which
suggests that overexpression of these genes probably in-
creases the number of malignant ESCC phenotypes and
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2003).
Concluding Remarks
Various molecular cytogenetic approaches have been
used to demonstrate the extensive genetic complexity asso-
ciatedwiththedifferentstagesofESCCandhaveidentified
key genes involved in esophageal cancer. Most of the un-
balanced chromosomal regions are similar in primary tu-
morsandcelllines,thusconfirmingthatcelllinesprovidea
reliable model for investigating the molecular mechanisms
involved in ESCC.
Specific chromosomal imbalances are associated
with the progression of esophageal tumors. Whereas gains
in 1q, 5p, 8q, 14q and losses in 4p, 13q and 18q are associ-
ated with the early stages of ESCC development, gains in
1p, 2p, 7p22.3, 8q, 8q24-qter and Xq and losses in 8p22-
pter, 11q14-qter, 13q and 21q are associated with advanced
stages. Gains involving 3q and 11q13 and losses involving
3p, 4q, 5q14-23, 9p and 18q are detected in both early and
advanced stages of ESCC. These regions harbor genes as-
sociated with essential cellular processes, such as signal
transduction, transcriptional regulation, cell proliferation
andcelldifferentiation,involvedinsignalizingcascadesre-
lated to cancer. Some imbalances, such as losses involving
4p, 9p and 11q and gains involving 1p36-32, 5p, 7q and
19p13.3, are poor prognostic markers. Gene overexpres-
sion most frequently affects oncogenes such as YES1,
TYMS, HEC, TGIF, NCOA3, BTAK, DCR3, E2F1, MYC,
EGFR, EGR2, CCND, FGF3/FGF4, EMS1, SAS, ERBB2,
PDGFR1, BCL2, MDS1 and PRKCI, whereas genomic
losses lead to the deletion of suppressor tumor genes such
as CDKN2A, MTAP and TP53. Identification of the role of
these critical genes in esophageal carcinogenesis will assist
the development of individualized target therapy that
should in turn improve the clinical outcome of ESCC pa-
tients.
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